New drug is safer and more effective in preventing heart tranplant rejection

April 23, 2004

Although cyclosporine is widely used to prevent rejection in organ transplant recipients over the long term, two problems remain for heart transplant patients: acute rejection, which occurs within the first three months after transplantation, and cardiac allograft vasculopathy, a thickening of the heart wall that can restrict blood flow.

Findings from the second year of a multi-center study of the new anti-rejection drug everolimus were presented Thursday (April 22, 2004) at the International Society for Heart and Lung Transplantation. According to lead author Howard Eisen, M.D., professor of medicine at Temple University School of Medicine and medical director of cardiac transplant at Temple University Hospital, everolimus is not only more effective, but also safer than standard therapy in preventing heart transplant rejection.

"Our findings over a two-year period reinforce what we learned in the first year of this study, as well as add to our understanding of everolimus. When combined with cyclosporine and steroids, everolimus prevents transplant rejection and lowers risk of infection and other complications better than the current standard anti-rejection therapy," said Eisen.

The Temple team currently has several research projects focused on the prevention of transplant rejection underway.
-end-


Temple University

Related Transplantation Articles from Brightsurf:

A revolutionary new treatment alternative to corneal transplantation
A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.

Fewer complications after organ transplantation
A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

Elderly patients also benefit from kidney transplantation
So far, kidney transplantation has generally not been offered to elderly patients (>75 years) because of the perioperative risks.

New material will allow abandoning bone marrow transplantation
Scientists from the National University of Science and Technology 'MISIS' developed nanomaterial, which will be able to restore the internal structure of bones damaged due to osteoporosis and osteomyelitis.

Fewer medical tests -- timely listing for transplantation
Younger patients would benefit greatly from kidney transplantation. Their expected remaining lifetime may even be doubled by having a transplant.

Uterus transplantation -- ethically just as problematic as altruistic surrogacy
In 2014, the first child to have been gestated in a donated uterus was born.

Advancing transplantation: Hepatitis C-infected organs safe for transplantation when followed by antiviral treatment
Twenty patients at Penn Medicine have been cured of the hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease, according to a study published today in Annals of Internal Medicine.

Transplantation followed by antiviral therapy cured hepatitis C
Twenty patients who received kidneys transplanted from hepatitis C virus (HCV)-infected donors experienced HCV cure, good quality of life, and excellent renal function at one year.

The Journal of Heart and Lung Transplantation: 50 years of heart transplantation progress
This month marks the 50th anniversary of the world's first human heart transplant performed at Groote Schuur Hospital in Cape Town by South African surgeon, Christiaan Barnard.

Older donor lungs should be considered for transplantation
With a scarcity of lungs available for transplantation, the use of lungs from donors older than age 60 has been shown to achieve reasonable outcomes and should be considered as a viable option, according to research published online today in The Annals of Thoracic Surgery.

Read More: Transplantation News and Transplantation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.